Combined natural killer T-cell-based immunotherapy eradicates established tumors in mice

Michele W L Teng, Jennifer A. Westwood, Phillip K. Darcy, Janelle Sharkey, Moriya Tsuji, Richard W. Franck, Steven A. Porcelli, Gurdyal S. Besra, Kazuyoshi Takeda, Hideo Yagita, Michael H. Kershaw, Markj Smyth

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

A rational monoclonal antibody (mAb)-based antitumor therapy approach has previously been shown to eradicate various established experimental and carcinogen-induced tumors in a majority of mice. This therapy comprised an agonistic mAb reactive with tumor necrosis factor-related apoptosis-inducing ligand receptor (DR5), expressed by tumor cells, an agonistic anti-CD40 mAb to mature dendritic cells, and an agonistic anti-4-1BB mAb to costimulate CD8 + T cells. Because agonists of CD40 have been toxic in patients, we were interested in substituting anti-CD40 mAb with other dendritic cell-maturing agents, such as glycolipid ligands recognized by invariant natural killer T (iNKT) cells. Here, we show that CD1d-restricted glycolipid ligands for iNKT cells effectively substitute for anti-CD40 mAb and reject established experimental mouse breast and renal tumors when used in combination with anti-DR5 and anti-4-1BB mAbs (termed "NKTMab" therapy). NKTMab therapy-induced tumor rejection was dependent on CD4+ and CD8 + T cells, NKT cells, and the cytokine IFN-γ. NKTMab therapy containing either α-galactosylceramide (α-GC) or α-C-galactosylceramide (α-c-GC) at high concentrations induced similar rates of tumor rejection in mice; however, toxicity was observed at the highest doses of α-GC (>250 ng/injection), limiting the use of this glycolipid. By contrast, even very low doses of α-c-GC (25 ng/injection) retained considerable antitumor activity when used in combination with anti-DR5/anti-4-1BB, and thus, α-c-GC showed a considerably greater therapeutic index. In summary, sequential tumor cell apoptosis and amplification of dendritic cell function by NKT cell agonists represents an exciting and novel approach for cancer treatment.

Original languageEnglish (US)
Pages (from-to)7495-7504
Number of pages10
JournalCancer Research
Volume67
Issue number15
DOIs
StatePublished - Aug 1 2007

Fingerprint

Natural Killer T-Cells
Immunotherapy
Monoclonal Antibodies
Glycolipids
Neoplasms
Dendritic Cells
Ligands
Therapeutics
TNF-Related Apoptosis-Inducing Ligand Receptors
Apoptosis
Galactosylceramides
T-Lymphocytes
Injections
Poisons
Carcinogens
Tumor Necrosis Factor-alpha
Breast Neoplasms
Cytokines
Kidney

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Teng, M. W. L., Westwood, J. A., Darcy, P. K., Sharkey, J., Tsuji, M., Franck, R. W., ... Smyth, M. (2007). Combined natural killer T-cell-based immunotherapy eradicates established tumors in mice. Cancer Research, 67(15), 7495-7504. https://doi.org/10.1158/0008-5472.CAN-07-0941

Combined natural killer T-cell-based immunotherapy eradicates established tumors in mice. / Teng, Michele W L; Westwood, Jennifer A.; Darcy, Phillip K.; Sharkey, Janelle; Tsuji, Moriya; Franck, Richard W.; Porcelli, Steven A.; Besra, Gurdyal S.; Takeda, Kazuyoshi; Yagita, Hideo; Kershaw, Michael H.; Smyth, Markj.

In: Cancer Research, Vol. 67, No. 15, 01.08.2007, p. 7495-7504.

Research output: Contribution to journalArticle

Teng, MWL, Westwood, JA, Darcy, PK, Sharkey, J, Tsuji, M, Franck, RW, Porcelli, SA, Besra, GS, Takeda, K, Yagita, H, Kershaw, MH & Smyth, M 2007, 'Combined natural killer T-cell-based immunotherapy eradicates established tumors in mice', Cancer Research, vol. 67, no. 15, pp. 7495-7504. https://doi.org/10.1158/0008-5472.CAN-07-0941
Teng MWL, Westwood JA, Darcy PK, Sharkey J, Tsuji M, Franck RW et al. Combined natural killer T-cell-based immunotherapy eradicates established tumors in mice. Cancer Research. 2007 Aug 1;67(15):7495-7504. https://doi.org/10.1158/0008-5472.CAN-07-0941
Teng, Michele W L ; Westwood, Jennifer A. ; Darcy, Phillip K. ; Sharkey, Janelle ; Tsuji, Moriya ; Franck, Richard W. ; Porcelli, Steven A. ; Besra, Gurdyal S. ; Takeda, Kazuyoshi ; Yagita, Hideo ; Kershaw, Michael H. ; Smyth, Markj. / Combined natural killer T-cell-based immunotherapy eradicates established tumors in mice. In: Cancer Research. 2007 ; Vol. 67, No. 15. pp. 7495-7504.
@article{a39624e26d2849e0ab5e319748c761b7,
title = "Combined natural killer T-cell-based immunotherapy eradicates established tumors in mice",
abstract = "A rational monoclonal antibody (mAb)-based antitumor therapy approach has previously been shown to eradicate various established experimental and carcinogen-induced tumors in a majority of mice. This therapy comprised an agonistic mAb reactive with tumor necrosis factor-related apoptosis-inducing ligand receptor (DR5), expressed by tumor cells, an agonistic anti-CD40 mAb to mature dendritic cells, and an agonistic anti-4-1BB mAb to costimulate CD8 + T cells. Because agonists of CD40 have been toxic in patients, we were interested in substituting anti-CD40 mAb with other dendritic cell-maturing agents, such as glycolipid ligands recognized by invariant natural killer T (iNKT) cells. Here, we show that CD1d-restricted glycolipid ligands for iNKT cells effectively substitute for anti-CD40 mAb and reject established experimental mouse breast and renal tumors when used in combination with anti-DR5 and anti-4-1BB mAbs (termed {"}NKTMab{"} therapy). NKTMab therapy-induced tumor rejection was dependent on CD4+ and CD8 + T cells, NKT cells, and the cytokine IFN-γ. NKTMab therapy containing either α-galactosylceramide (α-GC) or α-C-galactosylceramide (α-c-GC) at high concentrations induced similar rates of tumor rejection in mice; however, toxicity was observed at the highest doses of α-GC (>250 ng/injection), limiting the use of this glycolipid. By contrast, even very low doses of α-c-GC (25 ng/injection) retained considerable antitumor activity when used in combination with anti-DR5/anti-4-1BB, and thus, α-c-GC showed a considerably greater therapeutic index. In summary, sequential tumor cell apoptosis and amplification of dendritic cell function by NKT cell agonists represents an exciting and novel approach for cancer treatment.",
author = "Teng, {Michele W L} and Westwood, {Jennifer A.} and Darcy, {Phillip K.} and Janelle Sharkey and Moriya Tsuji and Franck, {Richard W.} and Porcelli, {Steven A.} and Besra, {Gurdyal S.} and Kazuyoshi Takeda and Hideo Yagita and Kershaw, {Michael H.} and Markj Smyth",
year = "2007",
month = "8",
day = "1",
doi = "10.1158/0008-5472.CAN-07-0941",
language = "English (US)",
volume = "67",
pages = "7495--7504",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Combined natural killer T-cell-based immunotherapy eradicates established tumors in mice

AU - Teng, Michele W L

AU - Westwood, Jennifer A.

AU - Darcy, Phillip K.

AU - Sharkey, Janelle

AU - Tsuji, Moriya

AU - Franck, Richard W.

AU - Porcelli, Steven A.

AU - Besra, Gurdyal S.

AU - Takeda, Kazuyoshi

AU - Yagita, Hideo

AU - Kershaw, Michael H.

AU - Smyth, Markj

PY - 2007/8/1

Y1 - 2007/8/1

N2 - A rational monoclonal antibody (mAb)-based antitumor therapy approach has previously been shown to eradicate various established experimental and carcinogen-induced tumors in a majority of mice. This therapy comprised an agonistic mAb reactive with tumor necrosis factor-related apoptosis-inducing ligand receptor (DR5), expressed by tumor cells, an agonistic anti-CD40 mAb to mature dendritic cells, and an agonistic anti-4-1BB mAb to costimulate CD8 + T cells. Because agonists of CD40 have been toxic in patients, we were interested in substituting anti-CD40 mAb with other dendritic cell-maturing agents, such as glycolipid ligands recognized by invariant natural killer T (iNKT) cells. Here, we show that CD1d-restricted glycolipid ligands for iNKT cells effectively substitute for anti-CD40 mAb and reject established experimental mouse breast and renal tumors when used in combination with anti-DR5 and anti-4-1BB mAbs (termed "NKTMab" therapy). NKTMab therapy-induced tumor rejection was dependent on CD4+ and CD8 + T cells, NKT cells, and the cytokine IFN-γ. NKTMab therapy containing either α-galactosylceramide (α-GC) or α-C-galactosylceramide (α-c-GC) at high concentrations induced similar rates of tumor rejection in mice; however, toxicity was observed at the highest doses of α-GC (>250 ng/injection), limiting the use of this glycolipid. By contrast, even very low doses of α-c-GC (25 ng/injection) retained considerable antitumor activity when used in combination with anti-DR5/anti-4-1BB, and thus, α-c-GC showed a considerably greater therapeutic index. In summary, sequential tumor cell apoptosis and amplification of dendritic cell function by NKT cell agonists represents an exciting and novel approach for cancer treatment.

AB - A rational monoclonal antibody (mAb)-based antitumor therapy approach has previously been shown to eradicate various established experimental and carcinogen-induced tumors in a majority of mice. This therapy comprised an agonistic mAb reactive with tumor necrosis factor-related apoptosis-inducing ligand receptor (DR5), expressed by tumor cells, an agonistic anti-CD40 mAb to mature dendritic cells, and an agonistic anti-4-1BB mAb to costimulate CD8 + T cells. Because agonists of CD40 have been toxic in patients, we were interested in substituting anti-CD40 mAb with other dendritic cell-maturing agents, such as glycolipid ligands recognized by invariant natural killer T (iNKT) cells. Here, we show that CD1d-restricted glycolipid ligands for iNKT cells effectively substitute for anti-CD40 mAb and reject established experimental mouse breast and renal tumors when used in combination with anti-DR5 and anti-4-1BB mAbs (termed "NKTMab" therapy). NKTMab therapy-induced tumor rejection was dependent on CD4+ and CD8 + T cells, NKT cells, and the cytokine IFN-γ. NKTMab therapy containing either α-galactosylceramide (α-GC) or α-C-galactosylceramide (α-c-GC) at high concentrations induced similar rates of tumor rejection in mice; however, toxicity was observed at the highest doses of α-GC (>250 ng/injection), limiting the use of this glycolipid. By contrast, even very low doses of α-c-GC (25 ng/injection) retained considerable antitumor activity when used in combination with anti-DR5/anti-4-1BB, and thus, α-c-GC showed a considerably greater therapeutic index. In summary, sequential tumor cell apoptosis and amplification of dendritic cell function by NKT cell agonists represents an exciting and novel approach for cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=34547628869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547628869&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-0941

DO - 10.1158/0008-5472.CAN-07-0941

M3 - Article

C2 - 17671220

AN - SCOPUS:34547628869

VL - 67

SP - 7495

EP - 7504

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 15

ER -